Beyond prostate cancer and Ewing sarcoma, PARP-1 inhibitors could be used to selectively kill Ets-1-expressing tumours in numerous cancers such as breast, lung, colorectal or ovarian carcinomas. This evidence concerns the gene PARP1 and prostate carcinoma.